Conference Coverage

AHA: Empagliflozin for T2D reduces heart failure endpoints

Publish date: November 25, 2015

 

AT THE AHA SCIENTIFIC SESSIONS

References

Dr. Inzucchi disclosed ties with Boehringer Ingelheim, Merck, Janssen, Novo Nordisk, Sanofi/Regeron, Intarcia, Lexicon, Paxel, Takeda, and Eli Lilly. He acknowledged CME funding to Yale University from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Abbot, Merck Sharp & Dohme, and Sanofi.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Efficacy of Patient Aligned Care Team Pharmacist Services in Reaching Diabetes and Hyperlipidemia Treatment Goals
Type 2 Diabetes ICYMI
Diabetic foot ulcer: Early closure optimal
Type 2 Diabetes ICYMI
Artificial pancreas improved glycemia after islet cell transplant
Type 2 Diabetes ICYMI
Equation Predicts Blindness, Amputation Risk in Diabetes
Type 2 Diabetes ICYMI
U.S. hospitalization rates overestimated for some causes
Type 2 Diabetes ICYMI
Breastfeeding cuts risk of progression from GDM to type 2 diabetes
Type 2 Diabetes ICYMI
Unsupervised, at-home closed-loop insulin delivery system
Type 2 Diabetes ICYMI
AHA: Broadening evidence for CABG over PCI in diabetics
Type 2 Diabetes ICYMI
Blood pressure above 140/80 worsens proteinuric diabetic kidney disease
Type 2 Diabetes ICYMI
Blood Pressure Above 140/80 Worsens Proteinuric Diabetic Kidney Disease
Type 2 Diabetes ICYMI

Related Articles